Pfizer’s Hospira issues recall for lots of hydromorphone and Levophed

Pfizer's Hospira issues voluntary recall for Levophed and hydromorphone.

Hospira, a unit of pharma giant Pfizer, issued a voluntary recall of one lot of the injectable pain medication hydromorphone and four lots of the blood pressure medicine Levophed due to the potential of a lack of sterility from a damaged sterility filter used in the production process.

The recall, which was posted on the FDA website, is for lots distributed the U.S., Puerto Rico, Singapore and Taiwan between May and July this year. To date, the company said, no adverse effects have been reported.

No batches of the product have been reported to contain microorganisms.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Hydromorphone hydrochloride is typically used to relieve moderate to severe pain, while Levophed (norepinephrine bitartrate) is used on adults for blood pressure control in certain acute hypotensive states.

Here is a list of the lots being recalled by the company.

In June, the company cited sterility concerns for a nationwide voluntary recall of 42 lots of vials used to inject sodium bicarbonate during surgery and in critical events. The recall added to the ongoing shortage of the drug. Pfizer acquired Hospira in 2015 as part of a $15 billion buyout.


Suggested Articles

Spectrum Pharmaceuticals has pulled its biologics license application for Rolontis because the FDA needs more CMC information.

Samsung BioLogics has faced scrutiny of a biosimilars joint venture. Now, officials are looking more closely into the company's 2016 public listing.

Lupin has indicated it has received another FDA warning letter as regulatory issues continue to pile up for the Indian drugmaker.